convertible security - - - (12,215)
Investment and other income 482 294 797 417
Change in fair value of
derivative instruments (2,401) (56) 1,123 (7,620)
Interest expense (643) (573) (1,267) (1,140)
Total other (expense)
and income (2,562) (335) 653 (20,558)
Net (loss) income $(12,104) $(3,757) $(15,991) $(30,593)
Net (loss) income per
share, basic $(0.43) $(0.14) $(0.57) $(1.23)
Net (loss) income per
share, diluted $(0.43) $(0.14) $(0.60) $(1.23)
Weighted average shares
outstanding, basic 28,313,056 25,952,342 28,305,810 24,815,680
Weighted average shares
outstanding, diluted 28,313,056 25,952,342 28,403,507 24,815,680
EMISPHERE TECHNOLOGIES, INC.
Condensed Balance Sheets (Unaudited)
As of June 30, 2007 and December 31, 2006
(in thousands)
June 30, December 31,
2007 2006
Assets:
Cash, cash equivalents, restricted cash and
investments $8,939 $21,533
Accounts receivable 487 216
Prepaid expenses and other current assets 893 1,082
Total current assets 10,319 22,831
Equipment and leasehold improvements, net 2,247 2,652
Purchased technology, net 1,675 1,794
Other assets 798 815
Total A
'/>"/>
SOURCE Emisphere Technologies, Inc.
 Copyright©2007 PR Newswire. | |
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery
of GLP-1 and PYY2.
Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial3.
Sygnis Pharma AG announces date for presentation of clinical
results4.
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis5.
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis6.
YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial7.
BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine8.
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis9.
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone10.
AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease11.
Protox Announces Positive Clinical Data from Prostate Cancer Study